Get access to our best features
Get access to our best features
Published 3 months ago

Biogen will stop selling its controversial Alzheimer’s drug Aduhelm

  • Biogen has announced that it will discontinue the sale and development of the Alzheimer's drug Aduhelm, refocusing efforts on their newly approved drug Leqembi.
  • The decision to drop Aduhelm is not due to safety or efficacy concerns, and the Swiss company Neurimmune will regain full rights to the medicine.
  • Biogen will redistribute resources from Aduhelm to other Alzheimer's treatments in their portfolio, such as BIIB080.
Insights by Ground AI
Does this summary seem wrong?

0 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 64% of the sources are Center
66% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)